NewLimit raises an additional $45 million
Five months after closing its Series B financing, USA-based NewLimit has raised an additional $45 million from Eli Lilly (NYSE: LLY), Duke Management Co, Section 32, and others on a $1.62 billion cap.
Insiders including Kleiner Perkins, Dimension, Abstract, Human Capital, and Boost also participated. This round was propelled by new technical breakthroughs following our Series B that set the stage for our first clinical study in a few years.
NewLimit is developing medicines that can restore youthful function in old cells through epigenetic reprogramming. Since itsw Series B, the company has already seen significant advances in our lead programs that give us the confidence to start planning clinical studies in the near term.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze